Pancreatic Cancer Drug Doubles Survival, Ships to Patients

For the first time in pancreatic cancer treatment history, patients are getting access to a drug that doubles their survival time compared to standard care.

Revolution Medicines announced Friday that it has started shipping daraxonrasib, an experimental pancreatic cancer treatment, directly to patients through an FDA-authorized early access program. The drug isn't officially approved yet, but the results were too promising to wait.

In April, the company released Phase 3 clinical trial results that stunned the medical community. Patients treated with daraxonrasib lived nearly twice as long as those receiving standard chemotherapy, an outcome never before seen in pancreatic cancer research.

Pancreatic cancer remains one of the deadliest diagnoses, with most patients facing limited treatment options and short survival times. Standard chemotherapy offers modest benefits at best, leaving families desperate for alternatives.

The moment Revolution announced its trial results, patients and their doctors started calling. The demand became so overwhelming that the company worked with the FDA to create an early access pathway, allowing the most critically ill patients to receive treatment before the formal approval process concludes.

CEO Mark Goldsmith confirmed the news at a medical conference in Chicago, speaking at an event held alongside the American Society of Clinical Oncology's annual meeting. His simple statement carried enormous weight for families waiting anxiously: "We are now shipping the drug."

The Ripple Effect

This early access program represents more than just one company's compassionate response. It signals a shift in how the FDA and pharmaceutical companies can work together when trial results show extraordinary promise for patients facing terminal diagnoses.

The success of daraxonrasib could also energize research into similar treatments for other hard-to-treat cancers. When one breakthrough happens, it often lights the path for others, bringing new hope to research areas that have seen little progress for years.

For pancreatic cancer patients who have watched loved ones battle this disease with few effective options, the arrival of daraxonrasib packages at cancer centers nationwide means something even more fundamental: time. Time to celebrate another birthday, attend a graduation, or simply share more ordinary moments with the people they love.

The FDA approval process continues in parallel, with formal authorization expected in the coming months.